University of Thessaly (UTH)
Παρακολούθηση της ανταπόκρισης ασθενών με χρόνια αυθόρμητη κνίδωση μέσω κλινικών, αιματολογικών, βιοχημικών και ανοσολογικών δεικτών προ και μετά ενδομυϊκής χορήγησης αυτόλογου ολικού αίματος
Abstract
dc:descriptionChronic Spontaneous Urticaria (CSU) is a chronic recurrent skin disease, with a significant impact on daily activity and quality of life of patients, as well as a significant impact on socio-economic health systems. Although studies on the application of new treatments regarding the disease are constantly increasing, the knowledge of the underlying pathogenetic mechanism is still lacking. In addition, the existing treatment options have not been shown to affect the natural course of the disease, while the effectiveness of some of them has not been systematically evaluated so far; this results largely from the marked lack of data regarding ongoing studies in respect to treatments’ mechanism of action. Equally important is the lack of specific biomarkers in order to predict the course and/or the severity of the disease and predispose the clinician about the patients’ response on the efficacy of the aforementioned treatments. In the present study, the clinical benefit of additional (add-on) intramuscular administration of autologous whole blood (AWBI) was evaluated in a group of CSU patients with H1-antihistamine-treatment refractory CSU symptoms and/or reported adverse effects due to H1-antihistamine treatment. For this purpose, 19 CSU patients underwent weekly intramuscular AWBI infusions for 8 weeks. Patients’ follow-up was monitored by clinical, hematologic, biochemical and immunological markers following peripheral blood sampling at baseline and in the 8th and 12th week. In order to better determine the underlying inflammatory profile of patients with CSU, as well as for the detection and estimation of possible prognostic biomarkers of patients' response to the administered treatment, the same immunological workup was also performed in a group of 17 healthy controls for comparison purposes.AWBI treatment was not accompanied by serious adverse events in patients, while it was followed by a significant improvement in symptoms and the quality of life in 15/19 patients (78.9%), as assessed by clinical and psychometric markers such as UAS7, DLQI and CU -Q2oL. Following a more specific patients’ stratification to "good or non-responders", based on the treatment response to AWBI, as estimated through variations of UAS7 scores, patients with diminished baseline D-dimer levels and elevated levels of cytokine IL-12p70 showed greater response to AWBI therapy. All patients presented decreased baseline plasma IFN-γ levels compared to controls, while the noted improvement to the clinical symptoms (in respect to ‘’good responders’’) was accompanied by a marked increase in IFN-γ plasma expression following the completion of the therapeutic intervention (8th week). All the patients, regardless of degree of treatment response (‘’good and non-responders’’), presented a gradual increase in plasma IL-27 expression during treatment (at 8th and 12th week).In conclusion, it was shown that intramuscular AWBI infusions can be a safe, alternative, add-on treatment option in CSU patients with symptoms resistant to H1-antihistamine treatment. In fact, baseline plasma levels of D-dimer and IL-12p70 can be used as reliable biomarkers to predict the effectiveness of the treatment.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kitsioulis, Nikolaos
- Κιτσιούλης, Νικόλαος
Subjects
dc:subject × 11Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/45403